Functional Safety
How SIL Assessment Works for Pharmaceutical Reactor Safety Systems
Vinit Pandey · Published 4 August 2026
In short: SIL assessment for pharmaceutical batch reactors must account for demand modes that occur only during specific process stages, such as an emergency cooling function only relevant during the reaction hold, rather than a continuously-active protection layer.
Key takeaways
- Demand rate calculations should reflect actual time-at-risk during the relevant batch stage, not the full cycle
- Production scheduling constraints on proof testing must be honestly reflected in SIL verification assumptions
- A shared reactor's safety function must satisfy the most demanding target SIL among all products using it
- A new, more hazardous route introduced to a shared vessel should trigger re-verification of existing SIFs
Many pharmaceutical reactor safety instrumented functions — such as emergency quench or dump systems — are only relevant during specific stages of the batch cycle, meaning the SIL target and demand rate calculation must reflect the actual time-at-risk during that stage, not the full batch cycle duration.
Proof testing of batch reactor safety systems is often constrained by production scheduling, since testing may require the vessel to be out of service; this operational reality needs to be reflected honestly in the proof test interval assumptions used during SIL verification, rather than assuming an idealised testing cadence.
Multi-product plants complicate SIL assessment further, since a safety instrumented function protecting a shared reactor may need to satisfy the most demanding target SIL among all the products the vessel is used for, not just the product being run at the time of assessment.
Where an existing pharmaceutical facility introduces a new, more hazardous synthesis route into a previously lower-risk multi-product reactor, existing safety instrumented functions on that vessel should be re-verified against the new scenario's target SIL rather than assumed adequate.